FDA Advisory Panel Considers Risks of Laparoscopic Power Morcellation

Share this content:
FDA Advisory Panel Considers Risks of Laparoscopic Power Morcellation
FDA Advisory Panel Considers Risks of Laparoscopic Power Morcellation

There's no way to guarantee that laparoscopic power morcellation for uterine fibroid removal or hysterectomy won't increase the risk of spreading undetected cancer to other parts of a woman's body, U.S. health advisers said Friday.

The advisory panel to the U.S. Food and Drug Administration also said that women who do undergo the procedure should sign a written consent stating that they understand the potential risks, the Associated Press reported.

RELATED: FDA Warns Against Morcellation for Uterine Fibroids

The panel's advisory opinion follows an April 17 warning from the FDA that the procedure can inadvertently spread cancerous tissue beyond a woman's uterus and into other parts of her body.

The FDA hasn't set a decision date on the use of power morcellator devices, the AP said. The agency isn't obliged to follow the advice or recommendations of its advisory committees but usually does so.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs